Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 318 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: MTX therapy Clear all

Conditions: Rheumatoid Arthritis
Interventions: Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®; Biological
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Phoenix, Arizona • Palmdale, California • Upland, California + 18 more

Conditions: Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Etoposide, Ixazomib Citrate, Laboratory Biomarker Analysis, Methotrexate, Prednisone, Rituximab, Therapeutic Hydrocortisone, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Medford, Massachusetts • New Brunswick, New Jersey + 2 more

Conditions: Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Interventions: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia
Interventions: cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 9 Years
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 108
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Tacrolimus, Methotrexate, Tocilizumab; Drug
Lead sponsor: William R. Drobyski, MD; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Rheumatoid Arthritis
Interventions: Combination of Minocycline and MTX or MTX alone, methotrexate; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 75 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Desmoid Tumor
Interventions: methotrexate, vinblastine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2006
U.S. locations: 36
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 28 more

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
Interventions: Fludarabine, Busulfan, GVHD Prophylaxis, Gemtuzumab Ozogamicin, Anti-Thymocyte Globulin, Isotretinoin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 1 Month to 30 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Graft Versus Host Disease
Interventions: Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil; Drug · Procedure
Lead sponsor: Monica Bhatia; Other
Eligibility: 3 Years to 20 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
Interventions: Atorvastatin, Methotrexate, Tacrolimus; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Graft-versus-host Disease (GVHD)
Interventions: Ruxolitinib, Extracorporeal photopheresis (ECP), Low-dose methotrexate (MTX), Mycophenolate mofetil (MMF), mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Infliximab, Rituximab, Pentostatin, Imatinib, Ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 38
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 28 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions: Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Idarubicin, Idelalisib, In Vitro Kinase Inhibitor Assay, Leucovorin Calcium, Methotrexate, Methylprednisolone Sodium Succinate, Ponatinib Hydrochloride, Rituximab, Ruxolitinib Phosphate, Sorafenib Tosylate, Sunitinib Malate, Vincristine Sulfate; Drug · Device · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 64 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, JAK Inhibitor, Melphalan, Methotrexate, Tacrolimus, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Rheumatoid Arthritis (RA)
Interventions: AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo; Drug
Lead sponsor: SynAct Pharma Aps; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania

Conditions: Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, Burkitt Leukemia, Burkitt Lymphoma, CD20 Positive, Childhood Acute Lymphoblastic Leukemia in Complete Remission, Lymphoblastic Lymphoma
Interventions: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ofatumumab, Vincristine Sulfate; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions: Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Other · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 30 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 27
States / cities: Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more

Conditions: Rheumatoid Arthritis
Interventions: LX3305 low dose, LX3305 mid dose, LX3305 high dose, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 13
States / cities: Gainesville, Florida • Orange Park, Florida • Orlando, Florida + 10 more

Conditions: Acute Lymphocytic Leukemia, Adult Lymphoblastic Lymphoma
Interventions: DNR, VCR, PEG-asp, CTX, Prednisone, Liposomal AraC, MTX, LCV, AraC, Etoposide, Dasatinib, Rituximab, Hydrocortisone; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 4
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 1 more

Conditions: Arthritis, Rheumatoid
Interventions: Methotrexate, Sulfasalazine, Hydroxychloroquine, Etanercept, Adalimumab; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 31
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 25 more

Conditions: Rheumatoid Arthritis
Interventions: Tregalizumab, Placebo; Drug
Lead sponsor: Biotest; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Paradise Valley, Arizona • Springfield, Illinois • Lincoln, Nebraska + 5 more

Conditions: AIDS-Related-Primary Central Nervous System Lymphoma
Interventions: Methotrexate, Rituximab, Leucovorin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pediatric Crohn's Disease
Interventions: Methotrexate, Sugar pill (placebo); Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: Up to 20 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 32
States / cities: Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more

Conditions: Rheumatoid Arthritis
Interventions: patterns of use of combination therapy and monotherapy; Other
Lead sponsor: Pfizer; Industry
Eligibility: Not listed
Enrollment: 9,159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 61
States / cities: Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more

Search by objective public record fields.

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant

Treatment of Early RA: Minocycline in Combination With Methotrexate vs Methotrexate Alone

Vinblastine and Methotrexate in Treating Children With Desmoid Tumors

Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Treatments Against RA and Effect on FDG-PET/CT

Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis